A review on Millepachine and its derivatives as potential multitarget anticancer agents

Biochem Biophys Res Commun. 2023 Nov 12:681:249-270. doi: 10.1016/j.bbrc.2023.09.044. Epub 2023 Sep 19.

Abstract

Chalcones have a long history of being used for many medical purposes. These are the most prestigious scaffolds in medicine. The potential of Millepachine and its derivatives to treat various malignancies has been demonstrated in this review. The anticancer effects of Millepachine and its derivatives on ovarian cancer, hepatocellular carcinoma, breast, liver, colon, cervical, prostate, stomach, and gliomas are highlighted in the current review. Several genes that are crucial in reducing the severity of the disease have been altered by these substances. They mainly work by preventing tubulin polymerizing. They also exhibit apoptosis and cell cycle arrest at the G2/M phase. Additionally, these compounds inhibit invasion and migration and have antiproliferative effects. Preclinical studies have shown that Millepachine and its derivatives offer exceptional potential for treating a number of cancers. These results need to be confirmed in clinical research in order to develop viable cancer therapies.

Keywords: G2/M arrest; Millepachine; Millepachine and its derivatives; Natural compounds; Tubulin polymerization.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis
  • Carcinoma, Hepatocellular*
  • Cell Line, Tumor
  • Cell Proliferation
  • Chalcones* / pharmacology
  • Chalcones* / therapeutic use
  • Drug Screening Assays, Antitumor
  • Humans
  • Liver Neoplasms*
  • Male
  • Structure-Activity Relationship
  • Tubulin / metabolism
  • Tubulin Modulators / pharmacology

Substances

  • millepachine
  • Chalcones
  • Antineoplastic Agents
  • Tubulin
  • Tubulin Modulators